55. Targeting the Genital Tract Mucosa with a Lipopeptide/Recombinant Adenovirus Prime/Boost Vaccine Induces Potent and Long-Lasting CD8+ T Cell Immunity Against Herpes: Importance of Myeloid Differentiation Factor 88. Xiuli Zhang; Xavier Dervillez; Aziz Alami Chentoufi; Tina Badakhshan; Ilham Bettahi & BenMohamed L. The Journal of Immunology2012In press.

54. Future of an “asymptomatic” T-cell epitope-based therapeutic herpes simplex vaccine. Dervillez X, Gottimukkala C, Kabbara KW, Nguyen C, Badakhshan T, Kim SK, Nesburn AB, Wechsler SL & BenMohamed L. Future Virology2012. 7(4): 371- 378.


53. The Herpes Simplex Virus Type 1 Latency Associated Transcript Inhibits Phenotypic and Functional Maturation of Dendritic Cells. Chentoufi, A. A.; X. Dervillez; G. Dasgupta; C Nguyen; K.W. Kabbara; J. Xianzhi; B. Nesburn; S. L. Wechsler, and BenMohamed L. Viral Immunology2012. 25(3): 204- 215.


52. Immunodominant “Asymptomatic” Herpes Simplex Virus Type 1 and Type 2 Protein Antigens Identified by Probing Whole ORFome Microarrays By Serum Antibodies From Seropositive Asymptomatic Versus Symptomatic Individuals. Dasgupta G, Chentoufi AA, Kalantari M, Falatoonzadeh P, Chun S, Lim CH, Felgner PL, Davies DH, BenMohamed LJournal of Virology201286(8):4358- 4369.


51. Towards a Rational Design of an Asymptomatic Clinical Herpes Vaccine: The Old, The New, and The Unknown…. Chentoufi, A. A.; E. Kritzer, D. Yu, B. Nesburn; and BenMohamed L. Clinical and Developmental Immunology2012. In press.


50. Discovery of potential diagnostic and vaccine antigens in herpes simplex virus-1 and -2 by proteome- wide antibody profiling. Kalantari-Dehaghi M, Chun S, Chentoufi A, Pablo J, Liang L, Dasgupta G, Molina DM, Jasinskas A, Nakajima-Sasaki R, Felgner J, Hermanson G, BenMohamed L, Felgner PL, Davies DH. Journal of Virology. 201286(8): 4328- 4339.


49. Chentoufi, A.A., E. Kritzer, M. Tran, G. Dasgupta, R. EA., J. Xianzhi, D. Carpenter, O. Osorio, A. B. Nesburn, S. L. Wechsler & L. BenMohamed. The Herpes Simplex Virus-1 Encoded Latency- Associated Transcript Promotes Dysfunctional Virus-Specific CD8+ T Cells in Latently Infected Trigeminal Ganglia: A Novel Immune Evasion Mechanism. Journal of Virology2011. 85(17): 9127- 38.


48. Allen SJ, Mott KR, Chentoufi AA, BenMohamed L, Wechsler SL, Ballantyne CM & Ghiasi H. CD11c controls the capacity of HSV-1 responses to limit virus replication during primary infection. Journal of Virology2011. 85(19):9945-55.


47. Rubbo PA, Tuaillon E, Nagot N, Chentoufi AA, Bollore K, Reynes J, Vendrell JP, BenMohamed L & Van de Perre P. HIV-1 Infection Impairs HSV-Specific CD4+ and CD8+ T Cell Response by Reducing Th1 Cytokines and CCR5 Ligand Secretion. Journal of Acquired Immune Deficiency Syndrome2011. 58(1):9-17.


46. Dasgupta G. & BenMohamed L. Of Mice and Not Humans: Reliable Pre-clinical Animal Models for Evaluation of Human Herpes Immunotherapeutic Vaccine Candidates? Vaccine2011. 29(35): 5824- 36.


45. Allen SJ, Hamrah P, Gate D, Mott KR, Mantopoulos D, Zheng L, Town T, Jones C, von Andrian UH, Freeman GJ, Sharpe AH, BenMohamed L, Ahmed R, Wechsler SL & Ghiasi H. The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. Journal of Virology2011. 85(9): 4184-97.


44. Perlaza BL., Sauzet JP. Brahimi K. BenMohamed L & Druilhe P. Interferon-γ, a valuable surrogate marker of protective immunity against P. falciparum pre-erythrocytic stages. Malaria Journal2011. 10(1): 27. 


43. Jiang, X. Chentoufi AA., Hsiang, C., Carpenter, D., Osorio, N., BenMohamed L. Fraser, NW., Jones, C., & Wechsler SL. The herpes simplex virus type 1 latency associated transcript can protect neuronal derived C1300 and Neuro2A cells from Granzyme B induced apoptosis and CD8+ T-cell killing. Journal of Virology2011. 85(5): 2325-32.


42. Dasgupta G, Chentoufi AA, You S, Falatoonzadeh P, Urbano LA, Akhtarmalik A, Nguyen K, Ablabutyan L, Nesburn AB & BenMohamed L. Engagement of TLR2 Reverses the Suppressor Function of Conjunctiva CD4+CD25+ Regulatory T Cells, and Promotes Herpes Simplex Virus Epitope-Specific CD4+CD25- Effector T Cell Responses. Investigative in Ophthalmology and Visual Sciences. 2011. 52(6): 3321-33.


41. Chentoufi AA, & BenMohamed L. Future Viral Vectors for the Delivery of Asymptomatic Herpes Epitopes-Based Immunotherapeutic Vaccines. Future Virology2010. 5(5): 525-528.

40. Renaudet O, Dasgupta G, Bettahi I, Shi A, Nesburn AB, Dumy P & BenMohamed L. Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity. PLoS One2010. 5(6): 11216.

39. Chentoufi AA, Dasgupta G, Nesburn AB, Bettahi I, Binder NR, Choudhury ZS, Chamberlain WD, Wechsler SL, & BenMohamed L. Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization. Clinical Vaccine Immunology2010. 17(3): 342-53.

38. Dasgupta G, Nesburn AB, Wechsler SL. & BenMohamed L. Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiology2010. 5:1-4.

37. Chentoufi A.A., Dasgupta G., Azeem A. Choudhury Z., Christensen N, Wechsler SL., Nesburn AB & BenMohamed L. A Novel Human Leukocyte Antigen (HLA-A*0201) Transgenic Rabbit Model to Evaluate the Protective Efficacy of Human CD8+ T-Cell Epitopes against Ocular Herpes Infection and Disease. The Journal of Immunology2010. 184(5): 2561-71.

36. Chentoufi AA., Nesburn AB & BenMohamed L. Recent Advances in Multivalent Self-Adjuvanting Glyco-lipopeptide Vaccine Strategies against Breast Cancer. Archivum Immunologiae et Therapiae Experimentalis2009. 57(6): 409-23.

35. Dasgupta G., Chentoufi AA., Wechsler SL., Nesburn AB & BenMohamed L. Herpes Simplex Virus Vaccine Development: Notes and Challenges from a Battlefield. Expert Review Vaccine2009. 8(8): 1023-35.

34. Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, Zhu X, Carpenter D, Wechsler SL, You S, & BenMohamed L. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8(+) T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunology (Nature Publishing Group)2009. 2(2): 129-43.

33. Mott KR, Chentoufi AA, Carpenter D, BenMohamed L, Wechsler SL & Ghiasi H. The role of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus on virus replication and pathogenicity. Investigative in Ophthalmology and Visual Science2009. 50(6): 2903-12.

32. Mott KR, Bresee CJ, Allen SJ, BenMohamed L, Wechsler SL & Ghiasi H. Level of Herpes Simplex Virus Type 1 latency correlates with severity of corneal scarring and exhaustion of CD8+ T cells in trigeminal ganglia of latently infected mice. Journal of Virology2009. 83(5): 2246-54.

31. Bettahi I; Dasgupta G; Renaudet O; Chentoufi AA; Zhang X; Carpenter D; Yoon S; Dumy P & BenMohamed L. Antitumor Activity of a Self-Adjuvanting Glyco-Lipopeptide Vaccine Bearing B-Cell, CD4+ and CD8+ T-Cell Epitopes. Cancer Immunology and Immunotherapy2009. 58(2): 187-200.

30. Chentoufi AA, Binder NR; Berka N, Durrand G, Nguyen A, Bettahi I, Maillere B & BenMohamed L. Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B. Journal of Virology2008. (23): 11792-802.

29. Zhang X, Castelli FA, Zhu X, Wu M, Maillère B & BenMohamed L. Gender-Dependent HLA-DR Restricted Epitopes Identified from the Herpes Simplex Virus Type 1 Glycoprotein D. Clinical Vaccine Immunology2008. (9): 1436-49.

28. Renaudet O, BenMohamed L, Dasgupta G, Bettahi I & Dumy P. Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glyco-lipopeptide cancer vaccine. Chemistry Enabling Drug Discovery (ChemMedChem). 2008. 3(5): 737-41.

27. Chentoufi AA, Zhang X, Lamberth K, Dasgupta G, Bettahi I, Nguyen A, Wu M, Zhu X, Mohebbi A, Buus S, Wechsler SL, Nesburn AB, BenMohamed L. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. The Journal of Immunology2008. 180(1): 426-37.

26. Carpenter D, Henderson G, Hsiang C, Osorio N, BenMohamed L, Jones C & Wechsler SL. Introducing point mutations into the ATGs of the putative open reading frames of the HSV-1 gene encoding the latency associated transcript (LAT) reduces its anti-apoptosis activity. Microbes and Pathogens2008. 44(2):98-102.

25. Bettahi I, Nesburn AB, Yoon S, Zhang X, Mohebbi A, Sue V, Vanderberg A, Wechsler SL & BenMohamed L. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Investigative Ophthalmology and Visual Science2007. 48(10): 4643-53.

24. Carpenter D, Hsiang C, Brown DJ, Jin L, Osorio N, BenMohamed L, Jones C & Wechsler SL. Stable cell lines expressing high levels of the herpes simplex virus type 1 LAT are refractory to caspase 3 activation and DNA laddering following cold shock induced apoptosis. Virology2007. 369(1): 12-8.

23. Nesburn AB, Bettahi I, Dasgupta G, Chentoufi AA, Zhang X, You S, Morishige N, Wahlert AJ, Brown DJ, Jester JV, Wechsler SL & BenMohamed L. Functional Foxp3+ CD4+ CD25(Bright+) “natural” regulatory T cells are abundant in rabbit conjunctiva and suppress virus-specific CD4+ and CD8+ effector T cells during ocular herpes infection. Journal of Virology2007. 81(14): 7647-61.

22. Nesburn AB, Bettahi I, Zhang X, Zhu X, Chamberlain W, Afifi RE, Wechsler SL & BenMohamed L. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocular Surface2006. 4(4): 178-87.

21. Bettahi I, Zhang X, Afifi RE & BenMohamed L. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunology2006. 19(2): 220-36.

20. Zhang X, Issagholian A, Berg EA, Fishman JB, Nesburn AB & BenMohamed L. Th-cytotoxic T- lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. Journal of Virology2005. 79(24): 15289-301.

19. Nesburn AB, Ramos TV, Zhu X, Asgarzadeh H, Nguyen V & BenMohamed L. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine2005. 23(7): 873-83.

18. Peng W, Henderson G, Inman M, BenMohamed L, Perng GC, Wechsler SL & Jones C. The locus encompassing the latency-associated transcript of herpes simplex virus type 1 interferes with and delays interferon expression in productively infected neuroblastoma cells and trigeminal Ganglia of acutely infected mice. Journal of Virology2005. 79(10): 6162-71.

17. BenMohamed L, Thomas A & Druilhe P. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infection and Immunity2004. 72(8): 4376-84.

16. Lo-Man R, Vichier-Guerre S, Perraut R, Dériaud E, Huteau V, BenMohamed L, Diop OM, Livingston PO, Bay S & Leclerc C. A fully synthetic therapeutic vaccine candidate targeting carcinoma- associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Research2004. 64(14): 4987-94.

15. Zhu X, Ramos TV, Gras-Masse H, Kaplan BE & BenMohamed L. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll- like receptor-2 pathway and trigger a Th1-dependent protective immunity. European Journal of Immunology2004. 4(11): 3102-14.

14. BenMohamed L, Bertrand G, McNamara CD, Gras-Masse H, Hammer J, Wechsler SL & Nesburn AB. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. Journal of Virology2003. 77(17): 9463- 73.

13. Vichier-Guerre S, Lo-Man R, BenMohamed L, Dériaud E, Kovats S, Leclerc C, Bay S. Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use. Journal of Peptide Research2003. 62(3): 117-24.

12. BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology2002. 106(1): 113-21.

11. BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. European Journal of Immunology2002. 32(8): 2274-81.

10. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines–yesterday, today, and tomorrow. Lancet Infectious Diseases2002. 2(7): 425-31.

9. Perng GC, Maguen B, Jin L, Mott KR, Kurylo J, BenMohamed L, Yukht A, Osorio N, Nesburn AB, Henderson G, Inman M, Jones C, Wechsler SL. A novel herpes simplex virus type 1 transcript (AL- RNA) antisense to the 5′ end of the latency-associated transcript produces a protein in infected rabbits. Journal of Virology2002. 76(16): 8003-10.

8. Brahimi K, Badell E, Sauzet JP, BenMohamed L, Daubersies P, Guérin-Marchand C, Snounou G, Druilhe P. Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo. Infection and Immunity2001. 69(6): 3845-52.

7. BenMohamed L, Thomas A, Bossus M, Brahimi K, Wubben J, Gras-Masse H, Druilhe P. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine2000. 18(25): 2843-55.

6. BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J, Diamond DJ. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Human Immunology2000. 61(8): 764-79.

5. Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, BenMohamed L, Slierendregt B, Eling W, Van Belkum A, Dubreuil G, Meis JF, Guérin-Marchand C, Cayphas S, Cohen J, Gras-Masse H, Druilhe P. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nature Medicine2000. 6(11): 1258-63.

4. Bossus M, BenMohamed L, Londono A, Barbier B, Tartar A, Druilhe P & Gras-Masse H. Improved detection of human antibodies to a Plasmodium antigen using a peptide modified with Aib residues. Journal of Peptide Science1997. 3(1): 47-53.

3. BenMohamed L, Gras-Masse H, Tartar A, Daubersies P, Brahimi K, Bossus M, Thomas A & Druilhe P. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. European Journal of Immunology1997. 27(5): 1242-53.

2. Bottius E, BenMohamed L, Brahimi K, Gras H, Lepers JP, Raharimalala L, Aikawa M, Meis J, Slierendregt B, Tartar A, Thomas A & Druilhe P. A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes. The Journal of Immunology1996. 156(8): 2874-84.

1. Fidock DA, Gras-Masse H, Lepers JP, Brahimi K, BenMohamed L, Mellouk S, Guerin-Marchand C, Londono A, Raharimalala L & Meis JF. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. The Journal of Immunology. 1994.153(1): 190-204.